Vantage Point Financial LLC Acquires Shares of 29,744 Oncolytics Biotech Inc. (NASDAQ:ONCY)

Vantage Point Financial LLC bought a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the 4th quarter, Holdings Channel reports. The fund bought 29,744 shares of the company’s stock, valued at approximately $27,000.

Separately, International Assets Investment Management LLC lifted its position in Oncolytics Biotech by 15.0% during the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after acquiring an additional 26,069 shares during the period. Hedge funds and other institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Stock Performance

Shares of NASDAQ ONCY opened at $0.69 on Tuesday. Oncolytics Biotech Inc. has a one year low of $0.67 and a one year high of $1.53. The firm has a market capitalization of $55.21 million, a P/E ratio of -2.56 and a beta of 1.29. The company’s fifty day moving average is $0.86 and its two-hundred day moving average is $0.98.

Analyst Ratings Changes

A number of research analysts have recently issued reports on ONCY shares. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a report on Monday. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, November 13th. Finally, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.